Rockwell Medical (RMTI) Lifted to “Hold” at BidaskClub
BidaskClub upgraded shares of Rockwell Medical (NASDAQ:RMTI) from a sell rating to a hold rating in a research report sent to investors on Friday.
Separately, Zacks Investment Research downgraded Rockwell Medical from a buy rating to a hold rating in a research note on Saturday, October 28th.
Shares of Rockwell Medical (RMTI) opened at $6.60 on Friday. Rockwell Medical has a 12 month low of $5.06 and a 12 month high of $8.98.
Several hedge funds have recently modified their holdings of RMTI. Bank of New York Mellon Corp grew its holdings in shares of Rockwell Medical by 6.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 249,489 shares of the company’s stock worth $2,136,000 after acquiring an additional 15,271 shares during the last quarter. Athos Capital Ltd acquired a new position in shares of Rockwell Medical in the 3rd quarter worth $6,834,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Rockwell Medical in the 3rd quarter worth $107,000. National Asset Management Inc. acquired a new position in shares of Rockwell Medical in the 2nd quarter worth $203,000. Finally, State Street Corp grew its holdings in shares of Rockwell Medical by 7.4% in the 2nd quarter. State Street Corp now owns 903,142 shares of the company’s stock worth $7,160,000 after acquiring an additional 62,094 shares during the last quarter. Institutional investors own 21.30% of the company’s stock.
WARNING: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/rockwell-medical-rmti-lifted-to-hold-at-bidaskclub/1771327.html.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.